Circulating alpha-fetoprotein-specific T-cell responses are associated with clinical outcomes after radiofrequency ablation or immunotherapy in hepatocellular carcinoma

Background: Circulating tumor antigen–specific T-cell responses are promising peripheral immune biomarkers associated with treatment efficacy, yet clinical translation is hampered by incomplete epitope maps and non-standardized assays. This study aimed to map the T-cell epitope repertoire of AFP and develop a PBMC-based assay to quantify circulating AFP-specific T-cell responses in HCC. Methods: CD8 + T-cell epitopes in AFP were screened using in silico prediction, peptide-PBMC coculture, peptide competitive binding assays, and immunization in HLA-transgenic mice, and then applied in clinical cohorts. Results: Totally, 48 CD8 + T-cell epitopes identified here and 20 from our previous study were confirmed immunogenic. These peptides were used to establish an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs. A total of 170 HCC patients with elevated serum AFP were included in two derivation cohorts: 80 patients treated with RFA and 90 receiving anti-PD-1 plus anti-VEGF therapy. In the RFA derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with DFS (AUC, 0.838; cutoff, 1.95-fold for DFS >12 vs. ≤12 mo). In the anti-PD-1 plus anti-VEGF derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with objective response and 6-month PFS (AUC, 0.850 and 0.863, respectively), with a unified 2.5-fold cutoff for outcome stratification. These findings in the immunotherapy setting were further validated in an independent external cohort of 50 HCC patients with elevated serum AFP receiving combined anti-PD-1 and anti-VEGF therapy. Conclusions: This study establishes an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs and supports their potential translational utility as a novel peripheral immune-monitoring biomarker associated with clinical outcomes in AFP-positive HCC patients.

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2026-11-19
DOI
https://doi.org/10.1097/hc9.0000000000001050
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circulating alpha-fetoprotein-specific T-cell responses are associated with clinical outcomes after radiofrequency ablation or immunotherapy in hepatocellular carcinoma

Yi Wu, Chuanlai Shen, Fangping Yue, Yandan Wu et al.
Hepatology Communications
Hepatocellular Carcinoma Treatment and Prognosis
article

Circulating alpha-fetoprotein-specific T-cell responses are associated with clinical outcomes after radiofrequency ablation or immunotherapy in hepatocellular carcinoma

Yi Wu, Chuanlai Shen, Fangping Yue, Yandan Wu, Qingwei Song, Yu Zhao, Dengyong Zhang, Song Yang, Wanliang Sun, Suyue Zhu, Shilong Song
article en

Abstract

Background: Circulating tumor antigen–specific T-cell responses are promising peripheral immune biomarkers associated with treatment efficacy, yet clinical translation is hampered by incomplete epitope maps and non-standardized assays. This study aimed to map the T-cell epitope repertoire of AFP and develop a PBMC-based assay to quantify circulating AFP-specific T-cell responses in HCC. Methods: CD8 + T-cell epitopes in AFP were screened using in silico prediction, peptide-PBMC coculture, peptide competitive binding assays, and immunization in HLA-transgenic mice, and then applied in clinical cohorts. Results: Totally, 48 CD8 + T-cell epitopes identified here and 20 from our previous study were confirmed immunogenic. These peptides were used to establish an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs. A total of 170 HCC patients with elevated serum AFP were included in two derivation cohorts: 80 patients treated with RFA and 90 receiving anti-PD-1 plus anti-VEGF therapy. In the RFA derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with DFS (AUC, 0.838; cutoff, 1.95-fold for DFS >12 vs. ≤12 mo). In the anti-PD-1 plus anti-VEGF derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with objective response and 6-month PFS (AUC, 0.850 and 0.863, respectively), with a unified 2.5-fold cutoff for outcome stratification. These findings in the immunotherapy setting were further validated in an independent external cohort of 50 HCC patients with elevated serum AFP receiving combined anti-PD-1 and anti-VEGF therapy. Conclusions: This study establishes an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs and supports their potential translational utility as a novel peripheral immune-monitoring biomarker associated with clinical outcomes in AFP-positive HCC patients.

Hepatology CommunicationsVol. 10(12)
Xuzhou Medical College (CN), Affiliated Hospital of Xuzhou Medical College (CN), First Affiliated Hospital of Bengbu Medical College (CN), Southeast University (CN)
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon